You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 17, 2024

~ Buy the VYXEOS (cytarabine; daunorubicin) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR VYXEOS

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for VYXEOS

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02286726 ↗	CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia	Completed	Celator Pharmaceuticals	Phase 2	2015-05-04	This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and who are at risk for not responding well to treatment. Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing.
NCT02286726 ↗	CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	2015-05-04	This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and who are at risk for not responding well to treatment. Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing.
NCT02286726 ↗	CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia	Completed	M.D. Anderson Cancer Center	Phase 2	2015-05-04	This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and who are at risk for not responding well to treatment. Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing.
NCT02533115 ↗	EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML	Approved for marketing	Celator Pharmaceuticals		1969-12-31	This study is a Phase IV Expanded Access Protocol (EAP) of CPX-351 in patients with secondary acute myeloid leukemia who are suitable for treatment with intensive chemotherapy.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for VYXEOS

Condition Name

Chart
Table

Condition Name for VYXEOS
Intervention	Trials
Acute Myeloid Leukemia	20
Recurrent Acute Myeloid Leukemia	9
Refractory Acute Myeloid Leukemia	8
Secondary Acute Myeloid Leukemia	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for VYXEOS
Intervention	Trials
Leukemia, Myeloid, Acute	35
Leukemia	35
Leukemia, Myeloid	33
Myelodysplastic Syndromes	15
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for VYXEOS

Trials by Country

Map
Table

Trials by Country for VYXEOS
Location	Trials
United States	148
Canada	13
China	3
United Kingdom	1
Israel	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for VYXEOS
Location	Trials
Texas	12
California	8
Washington	7
New York	6
Georgia	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for VYXEOS

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for VYXEOS
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	22
Phase 1/Phase 2	7
[disabled in preview]	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for VYXEOS
Clinical Trial Phase	Trials
Recruiting	25
Not yet recruiting	11
Active, not recruiting	3
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VYXEOS

Sponsor Name

Chart
Table

Sponsor Name for VYXEOS
Sponsor	Trials
National Cancer Institute (NCI)	21
Jazz Pharmaceuticals	17
M.D. Anderson Cancer Center	7
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for VYXEOS
Sponsor	Trials
Other	39
Industry	27
NIH	22
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.